Literature DB >> 31834530

Acute cognitive disorder as the initial manifestation of nitrous oxide abusing: a case report.

Qiuyan Shen1, Haitao Lu1, Hui Wang1, Yanming Xu2.   

Abstract

Nitrous oxide (N2O) is a colorless, odorless gas used as an anesthetic and analgesic. It is also abused as a recreational drug, and such abuse is associated with neurological disorders and psychiatric complications such as myelopathy and, rarely, cognitive impairment. Its abuse has not been associated with acute cognitive decline. Here, we report a young girl who presented with acute cognitive impairment after excessive recreational inhalation of nitrous oxide and who recovered completely after vitamin B12 supplementation. We conclude that nitrous oxide abuse can cause acute cognitive impairment, and that this diagnosis should be considered if a patient initially presents with acute cognitive decline.

Entities:  

Keywords:  Abusing; Cognitive disorders; Nitrous oxide

Mesh:

Substances:

Year:  2019        PMID: 31834530     DOI: 10.1007/s10072-019-04183-w

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  6 in total

1.  Persistent cognitive functioning deficits in operating rooms: two cases.

Authors:  Elsa Dreyfus; Eve Tramoni; Marie-Pascale Lehucher-Michel
Journal:  Int Arch Occup Environ Health       Date:  2008-02-08       Impact factor: 3.015

2.  Psychotropic analgesic nitrous oxide for acute cocaine withdrawal in man.

Authors:  Mark A Gillman; Frederick J Lichtigfeld; Nadine Harker
Journal:  Int J Neurosci       Date:  2006-07       Impact factor: 2.292

3.  Nitrous Oxide for Treatment-Resistant Major Depression: A Proof-of-Concept Trial.

Authors:  Peter Nagele; Andreas Duma; Michael Kopec; Marie Anne Gebara; Alireza Parsoei; Marie Walker; Alvin Janski; Vassilis N Panagopoulos; Pilar Cristancho; J Philip Miller; Charles F Zorumski; Charles R Conway
Journal:  Biol Psychiatry       Date:  2014-12-09       Impact factor: 13.382

Review 4.  Recreational nitrous oxide use: Prevalence and risks.

Authors:  Jan van Amsterdam; Ton Nabben; Wim van den Brink
Journal:  Regul Toxicol Pharmacol       Date:  2015-10-22       Impact factor: 3.271

5.  Psychomotor function during mild narcosis induced by subanesthetic level of nitrous oxide: individual susceptibility beyond gender effect.

Authors:  Miroljub Jakovljević; Gaj Vidmar; Igor B Mekjavic
Journal:  Undersea Hyperb Med       Date:  2012 Nov-Dec       Impact factor: 0.698

Review 6.  Neurologic, psychiatric, and other medical manifestations of nitrous oxide abuse: A systematic review of the case literature.

Authors:  Amir Garakani; Robert J Jaffe; Dipal Savla; Alison K Welch; Caroline A Protin; Ethan O Bryson; David M McDowell
Journal:  Am J Addict       Date:  2016-04-01
  6 in total
  4 in total

Review 1.  Recreational Nitrous Oxide Abuse: Prevalence, Neurotoxicity, and Treatment.

Authors:  Yuanyuan Xiang; Lei Li; Xiaotong Ma; Shan Li; Yuan Xue; Peng Yan; Meijie Chen; Junwei Wu
Journal:  Neurotox Res       Date:  2021-03-26       Impact factor: 3.911

2.  Alleviating Oxidative Damage-Induced Telomere Attrition: a Potential Mechanism for Inhibition by Folic Acid of Apoptosis in Neural Stem Cells.

Authors:  Zhenshu Li; Wen Li; Dezheng Zhou; Jing Zhao; Yue Ma; Ling Huang; Cuixia Dong; John X Wilson; Guowei Huang
Journal:  Mol Neurobiol       Date:  2021-11-05       Impact factor: 5.590

3.  Effect of hyperbaric oxygen therapy on cognitive dysfunction induced by nitrous oxide abuse: protocol of a randomised, double-blinded, placebo-controlled trial.

Authors:  Dan Luo; Lu Tan; Danling Shen; Mingfeng Lai; Qiao Tang; Jiajun Xu; Jing Li
Journal:  BMJ Open       Date:  2022-04-22       Impact factor: 3.006

4.  Reversible Neuropsychiatric Disturbances Caused by Nitrous Oxide Toxicity: Clinical, Imaging and Electrophysiological Profiles of 21 Patients with 6-12 Months Follow-up.

Authors:  Rui Zheng; Qinzhou Wang; Mingyuan Li; Fuchen Liu; Yongqing Zhang; Bing Zhao; Yuan Sun; Dong Zhang; Chuanzhu Yan; Yuying Zhao; Wei Li
Journal:  Neuropsychiatr Dis Treat       Date:  2020-11-23       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.